We are very pleased to go forward as a minority partner to Nordic Capital in BWXT Medical’s future growth given the expertise and deep resources they bring to this business and the market.” “We are excited about the next step as Nordic Capital sees significant potential to scale the business and expand access to cutting-edge radiopharmaceutical therapy,” said Christian Hedegaard, partner, Nordic Capital Advisors. “Nordic Capital has a long track record of successful investments across both pharmaceuticals and life sciences, and radiopharmaceuticals sit squarely at the intersection of the two. That sector depth, combined with strong conviction in the BWXT Medical team’s capabilities, created a strong foundation for this partnership.” Article contentBWXT cautions that this release contains forward-looking statements, including, without limitation, statements relating to the anticipated benefits of the divestiture of its medical business.